



Medical Conditions or other indications for administration of PCV13 and administration and revaccination with PPSV23

● 2–5 years old* †
 ● 6–64 years old
 ● ≥65 years old

Risk Group	Underlying Medical condition	Single dose of PCV13*				PPSV23				
		Recommended				Recommended		Revaccination at 5 years		
Immunocompetent persons	Chronic heart disease [§]	●		●		●	●	●	●	
	Chronic lung disease [§]	●		●		●	●	●	●	
	Diabetes Mellitus	●		●		●	●	●	●	
	CSF leaks	●	●	●		●	●	●	●	
	Cochlear implants	●	●	●		●	●	●	●	
	Alcoholism			●			●	●	●	
	Chronic liver disease			●			●	●	●	
	Cigarette smoking Asthma			●			●	●	●	
Immunocompromised Persons:		●	●	●		●	●	●	●	●

Sickle cell disease or other hemaglobinopathies •Congenital or acquired asplenia •Congenital or acquired immunodeficiencies[†] •HIV infection •Chronic renal failure •Nephrotic syndrome•Leukemia •Lymphoma •Hodgkin disease •Generalized malignancy •Iatrogenic immunosuppression (including immunosuppressive drugs, long-term systemic corticosteroids and radiation therapy) •Solid organ transplant •Multiple myeloma •Those living in residential care centers

*2 doses of PCV13, at least 8 weeks apart if unvaccinated or any incomplete schedule of <3 doses.
 †PCV13 approved for 2–5 years olds if treated with high-dose oral corticosteroid therapy. Not approved for asthma-only diagnosis in 6–18 year olds.
 §PCV13: Particularly cyanotic congenital heart disease and cardiac failure in 2–5 year olds.
 PPSV23: Chronic obstructive pulmonary disease, emphysema and asthma in persons ≥6 years of age.
 ‡Includes B–(humoral) or T-lymphocyte deficiency; complement deficiencies, particularly C1, C2, C3, and C4 deficiency; and phagocytic disorders (excluding chronic granulomatous disease).